1. Home
  2. NXP vs DBVT Comparison

NXP vs DBVT Comparison

Compare NXP & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Select Tax Free Income Portfolio

NXP

Nuveen Select Tax Free Income Portfolio

HOLD

Current Price

$14.12

Market Cap

743.2M

Sector

Finance

ML Signal

HOLD

DBVT

DBV Technologies S.A.

HOLD

Current Price

$17.59

Market Cap

769.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NXP
DBVT
Founded
1992
2002
Country
United States
France
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
743.2M
769.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NXP
DBVT
Price
$14.12
$17.59
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$31.75
AVG Volume (30 Days)
70.0K
611.1K
Earning Date
01-01-0001
10-28-2025
Dividend Yield
4.04%
N/A
EPS Growth
N/A
N/A
EPS
0.54
N/A
Revenue
N/A
$5,502,000.00
Revenue This Year
N/A
$1,768.71
Revenue Next Year
N/A
$1,028.88
P/E Ratio
$26.81
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.91
$3.30
52 Week High
$14.89
$26.19

Technical Indicators

Market Signals
Indicator
NXP
DBVT
Relative Strength Index (RSI) 40.99 49.87
Support Level $14.06 $16.49
Resistance Level $14.19 $19.62
Average True Range (ATR) 0.10 1.49
MACD 0.00 -0.49
Stochastic Oscillator 51.52 12.84

Price Performance

Historical Comparison
NXP
DBVT

About NXP Nuveen Select Tax Free Income Portfolio

Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund invests a majority of its assets in municipal securities and other related investments, the income from which is exempt from regular federal income tax and federal alternative minimum tax.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: